LAVAL, QC, Aug. 26 /CNW Telbec/ - The Laval-based firm Algorithme Pharma
is pleased to announce that it has achieved its goal of securing a European
facility through its acquisition of Simbec Research Ltd in Merthyr Tydfil,
Wales. This news comes only six weeks after confirming the purchase of another
clinical research centre in Baltimore, Maryland.
This important acquisition will enable Algorithme Pharma, a worldwide
leader in clinical research and bioanalysis, to continue its international
expansion plans, establish a foothold in Europe for the very first time in its
history and, most importantly, obtain additional advanced scientific and
medical expertise for its North American teams.
"Given the considerable growth of our "international" clientele, it
became necessary to acquire a location in Europe in order to better serve our
fast-growing market once we had expanded to the United States. The acquisition
of this strategically-located and highly-respected clinical research centre is
the first step in our European expansion strategy and provides us with an
important base for future growth in the European market," explains President
and Chief Executive Officer of Algorithme Pharma, Louis Caillé.
Simbec Research Ltd will continue its activities at its headquarters as a
new division of Algorithme Pharma. Simbec, along with two other Phase I
clinical research centres in the United Kingdom, was recently given the
official accreditation by the Medecine Healthcare Regulatory Agency (MHRA),
thereby joining a very select group of companies that has earned the trust of
governmental regulatory authorities. The Simbec centre has specialized in
Phase I and IIa drug development clinical trials for some thirty years.
"The combination of Simbec Research and Algorithme Pharma offers great
promise, both for our employees and our clients and we are delighted to be
adding our Phase I expertise to Algorithme's existing capacity. Having
established a strong business in the area of Clinical Research and Development
we now look forward with confidence to a future as part of the enlarged
Algorithme Pharma Group of companies", adds Brian Hallisey, Managing Director
of Simbec Research Ltd.
The new Phase I and IIa United Kingdom location for clinical research
includes a 38,000-square-foot facility with 48 beds (all used by the Intensive
Monitoring Unit), divided into five separate research units, making it
possible to carry out a number of studies simultaneously. With this addition,
Algorithme Pharma will increase its production capacity in Phase I and IIa
drug development clinical trials. Simbec is a leader in clinical trials and
bioanalysis and has been providing contract clinical research services to
large pharmaceutical research and development companies for over 30 years. The
staff of the new Algorithme Pharma division in the United Kingdom is composed
of a core team of approximately 100 employees who will join those already
working at company locations in Montreal and Laval, Canada and Baltimore,
About Algorithme Pharma - As a worldwide leader in clinical research and
bioanalysis, Algorithme Pharma provides a wide range of services for
bioequivalence and early stage development (Phase I/IIa) studies to the
generic, pharmaceutical, and bio-technology industries. In addition to its
multi-unit clinical facilities in Canada, the United States and the United
Kingdom (more than 400 beds) and with its new dedicated state-of-the-art
facility for Phase I clinical trials in Montreal, Algorithme Pharma offers
different services including protocol designs, CTD/ICH clinical reports, data
management, biostatistics, quality assurance (QA) and regulatory affairs.
Successfully audited by US FDA, Canada's TPD, Brazil's ANVISA, France's
AFSSAPS, UK's MHRA and more recently Austria's AGES regulatory authorities,
Algorithme Pharma conducts over 275 clinical trials per year. Proud winner of
Canada's 50 Best Managed Companies since 2003, Algorithme Pharma's main
success resides in the flexibility and commitment of its 600 + dedicated and
knowledgeable employees to deliver first-class service to each client.
For further information:
For further information: Media relations: Ingrid Saumart, (514)
490-0206, email@example.com; Marius S. Brisson, President; Source: Mr.
Louis Caillé, President & Chief Executive Officer, Algorithme Pharma;